GlaxoSmithKline plans 20 new drugs for regulatory approval
In a research and development presentation for investors, GSK said seven of the new drugs that might be filed with regulators were in advanced late-stage development.
The company also revealed advanced and early-stage projects in six core areas, including HIV and other infections, respiratory medicine, oncology, immuno-inflammation, vaccines and rare diseases.
The portfolio represents some of the latest scientific achievements from GSK's research and development organization and its more than 1,500 company and academic collaborations, according to GSK.
The company believes approximately 80 percent of the medicines and vaccines presented have the potential to be "first-in-class" with novel mechanisms of action. As a result, many of these potential medicines and vaccines may offer benefits beyond current standards of care and, in some cases, could radically transform how patients are treated. ■